Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Taro Pharm Inds (TARO)

Taro Pharm Inds (TARO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,789,773
  • Shares Outstanding, K 38,258
  • Annual Sales, $ 669,890 K
  • Annual Income, $ 281,780 K
  • 60-Month Beta 0.60
  • Price/Sales 4.15
  • Price/Cash Flow 9.32
  • Price/Book 1.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 1.53
  • Number of Estimates 1
  • High Estimate 1.53
  • Low Estimate 1.53
  • Prior Year 1.52
  • Growth Rate Est. (year over year) +0.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.20 +1.00%
on 02/14/20
86.86 -16.05%
on 01/16/20
-13.35 (-15.47%)
since 01/14/20
3-Month
72.20 +1.00%
on 02/14/20
99.69 -26.85%
on 12/06/19
-3.30 (-4.33%)
since 11/14/19
52-Week
72.20 +1.00%
on 02/14/20
109.42 -33.36%
on 04/29/19
-31.51 (-30.17%)
since 02/14/19

Most Recent Stories

More News
Taro Pharmaceutical (TARO) Surpasses Q3 Earnings Estimates

Taro (TARO) delivered earnings and revenue surprises of 14.29% and -14.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

TARO : 72.92 (+0.36%)
Taro: Fiscal 3Q Earnings Snapshot

HAIFA BAY, Israel (AP) _ Taro Pharmaceutical Industries Ltd. (TARO) on Monday reported fiscal third-quarter net income of $67.7 million.

TARO : 72.92 (+0.36%)
Taro Provides Results for December 31, 2019

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited financial results for the three and nine months ended December 31, 2019.

TARO : 72.92 (+0.36%)
Taro to Announce Third Quarter Results on February 3, 2020

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2019, after the close of market on Monday,...

TARO : 72.92 (+0.36%)
Taro Pharmaceuticals U.S.A., Inc. Issues Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles

--Due to Cross-Contamination With Enalapril Maleate

TARO : 72.92 (+0.36%)
Taro Announces Final Results of Its Tender Offer

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or the "Company") today announced the final results of its modified "Dutch auction" tender offer to repurchase up to $225 million in value of its...

TARO : 72.92 (+0.36%)
CORRECTING and REPLACING Taro Announces Preliminary Results of Its Tender Offer

Third paragraph, second sentence of release should read: "...announced until at least December 19, 2019..." (instead of announced until at least December 19, 2020...).

TARO : 72.92 (+0.36%)
Taro Announces Preliminary Results of Its Tender Offer

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $225 million in value...

TARO : 72.92 (+0.36%)
Taro Announces Resignation of Chief Financial Officer

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today that it has accepted the resignation of its Chief Financial Officer, Mariano Balaguer, effective January 3, 2020....

TARO : 72.92 (+0.36%)
Taro Announces Commencement of Tender Offer to Repurchase up to $225 Million in Value of Its Ordinary Shares

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today that it has commenced a modified "Dutch auction" tender offer to repurchase up to $225 million in value of its...

TARO : 72.92 (+0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade TARO with:

Business Summary

Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals...

See More

Key Turning Points

2nd Resistance Point 73.72
1st Resistance Point 73.32
Last Price 72.92
1st Support Level 72.36
2nd Support Level 71.80

See More

52-Week High 109.42
Fibonacci 61.8% 95.20
Fibonacci 50% 90.81
Fibonacci 38.2% 86.42
Last Price 72.92
52-Week Low 72.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar